The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
Executive Summary
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
You may also be interested in...
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Part D Price Negotiation Round One: Several Likely Candidates May Not Feel The Cut
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.
Medicare Price ‘Negotiation’ : Manufacturer Compliance Gets Tougher Enforcement Provision
As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.